Program
danicamtiv
Also written as “Danicamtiv” and “MYK-491”.
Its studies are mostly in Cardiomyopathy, Dilated · Heart Failure, led by 2 companies.
Furthest: phase 3, since Feb 14, 20187 company-led studies, 2 open or runningNext primary completion: Sep 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 50 open or running | phase 2since Feb 14, 2018 | Feb 14, 2018 | none ahead |
| Kardigan | 22 open or running | phase 3since Sep 23, 2025 | Sep 23, 2025 | Sep 2027phase 3 · NCT07210723 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 14, 2018First study: phase 2 study in Cardiomyopathy, DilatedNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT03447990 · 52 enrolled · United States, France, Germany and more
- Sep 9, 2020Phase 2 study in Campomelic DysplasiaBristol-Myers Squibb · NCT04572893 · 41 enrolled · United States, Germany, Spain and more
- Mar 29, 2023Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT05806359 · 33 enrolled · United States
- Jul 11, 2023Phase 1 study in Heart Failure With Reduced Ejection FractionBristol-Myers Squibb · NCT05952089 · 13 enrolled · United States
- Aug 31, 2023Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT06027437 · 21 enrolled · United States
- Sep 23, 2025Kardigan's first study: phase 3 study in Symptomatic Genetic Dilated CardiomyopathyNew to KardiganKardigan · NCT07210723 · 332 planned · United States, Belgium, Denmark and more
- Jul 20, 2026Phase 3 study in Symptomatic Genetic Dilated Cardiomyopathy (DCM)Kardigan · NCT07771465 · 332 planned · United States, Belgium, Denmark and more
Ahead
- Sep 2027Primary completion: phase 3 study in Symptomatic Genetic Dilated CardiomyopathyKardigan · NCT07210723
- Nov 2032Primary completion: phase 3 study in Symptomatic Genetic Dilated Cardiomyopathy (DCM)Kardigan · NCT07771465
TargetBeta
“Cardiac myosin activator”ChEMBL 37, by rule
Other programs on the same 7 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| mavacamtenrule | Bristol-Myers Squibb | phase 4 | 20 |
| omecamtiv mecarbilrule | Cytokinetics | phase 3 | 16 |
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07771465Symptomatic Genetic Dilated Cardiomyopathy (DCM) · United States, Belgium, Denmark and more | 3 | Recruiting | Kardigan | Nov 2032 | 332 |
| NCT07210723Symptomatic Genetic Dilated Cardiomyopathy · United States, Belgium, Denmark and more | 3 | Recruiting | Kardigan | Sep 2027 | 332 |
| NCT06027437Healthy Volunteers · United States | 1 | Completed | Bristol-Myers Squibb | Nov 10, 2023 | 21 |
| NCT05952089Heart Failure With Reduced Ejection Fraction · United States | 1 | Completed | Bristol-Myers Squibb | Mar 15, 2024 | 13 |
| NCT05806359Healthy Volunteers · United States | 1 | Completed | Bristol-Myers Squibb | Aug 14, 2023 | 33 |
| NCT04572893Campomelic Dysplasia · United States, Germany, Spain and more | 2 | Terminated | Bristol-Myers Squibb | Feb 22, 2024 | 41 |
| NCT03447990Cardiomyopathy, Dilated · United States, France, Germany and more | 2 | Completed | Bristol-Myers Squibb | Oct 24, 2019 | 52 |
How it is read
Names in the registry
- “Danicamtiv”, 4 entries
- “danicamtiv”, 2 entries
- “MYK-491”, 1 entry
Conditions, from the studies’ own filings
- Cardiomyopathy, Dilated, 4 studies
- Heart Failure, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.